MERCK & CO INC

The holder set is conventional for a large pharma: Vanguard, BlackRock, and State Street dominate the passive layer; Capital Research, T. Rowe Price, and active healthcare specialists provide the conviction layer. The absence of aggressive accumulation or distribution in the static snapshot suggests holders are waiting for pipeline data — Keytruda successor approval, or the resolution of the patent-timeline uncertainty — before making meaningful sizing decisions.

The changes block is unusable this quarter due to a prior-quarter join failure. Whether institutional flows were net-positive or net-negative in Q1 is unreadable from the data. What is readable is Merck's continued role as a dividend-paying, pipeline-optionality healthcare name: held broadly, sized traditionally, and viewed as a sector core rather than a high-conviction alpha driver.